Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis.

Saved in:
Bibliographic Details
Title: Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis.
Authors: Yanagisawa T; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.; Department of Urology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan., Quhal F; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.; Department of Urology, King Fahad Specialist Hospital, Dammam, 32253, Saudi Arabia., Kawada T; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.; Department of Urology, Okayama University Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama, 700-8530, Japan., Bekku K; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.; Department of Urology, Okayama University Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama, 700-8530, Japan., Laukhtina E; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.; Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119435, Russia., Rajwa P; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.; Department of Urology, Medical University of Silesia, Zabrze, 41-800, Poland., Deimling MV; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany., Chlosta M; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.; Clinic of Urology & Urological Oncology, Jagiellonian University, Krakow, 30-688, Poland., Pradere B; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.; Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, 31130, France., Karakiewicz PI; Cancer Prognostics & Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, H2X 0A9, Canada., Mori K; Department of Urology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan., Kimura T; Department of Urology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan., Schmidinger M; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria., Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, 19328, Jordan.; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.; Department of Urology, Second Faculty of Medicine, Charles University, Prague, 15006, Czech Republic.; Department of Urology, Weill Cornell Medical College, NY 10021, USA.; Karl Landsteiner Institute of Urology & Andrology, Vienna, 1090, Austria.
Source: Immunotherapy [Immunotherapy] 2023 Oct; Vol. 15 (15), pp. 1309-1322. Date of Electronic Publication: 2023 Sep 11.
Publication Type: Meta-Analysis; Journal Article; Review
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101485158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1750-7448
DOI:10.2217/imt-2023-0039